Nav: Home

Pay now or pay more later: Treating hepatitis C

May 09, 2016

The price of curing hepatitis C in the long term is much cheaper than the ongoing expense of older therapies or delayed treatments, including liver transplants, according to a group of studies published this month in a special edition of the American Journal of Managed Care.

"Many policymakers have focused on what they see as a high price for three months of therapy, but the value of curing hepatitis C lasts a lifetime," said Darius Lakdawalla, Quintiles Professor of Pharmaceutical Development and Regulatory Innovation at the USC Schaeffer Center for Health Policy and Economics.

An estimated 3.5 million Americans suffer from hepatitis C, and half have not yet been diagnosed, according to federal health statistics. Most hepatitis C patients are baby boomers who became infected through blood transfusions before the 1980s, when new federal regulations for the blood supply went into effect. A record number of Americans - 19,659 - died of hepatitis C in 2014, the Centers for Disease Control and Prevention reported last week.

According to the researchers who led the studies, only 13 percent to 36 percent of U.S. patients who have chronic hepatitis C (HCV) have been treated and even fewer have completed the treatment regimen that would wipe out their disease.

The economic studies were funded by the Illinois-based pharmaceutical company AbbVie Inc., and were conducted by teams of national researchers, which included Lakdawalla. The studies showed that financing treatment of hepatitis C would not only save lives but ease future costs for Medicare and reduce the need for liver transplants.

The researchers also found that an expansion of screenings and treatment to all hepatitis C patients, regardless of what stage of the disease they are in, would generate more than $800 billion in benefits - due largely to improved health and longer lives - over 20 years.

For these studies, the economists and clinicians examined key issues affecting coverage and patient access to the cures:
  • In one study, researchers assessed the problem of relying on private insurers to treat hepatitis C patients, when much of the benefit of curing the disease ends up accruing to Medicare and other private insurers that a patient might switch to in the future. Medicare may end up footing the bill for expensive complications if fewer patients are successfully treated at earlier disease stages.

Lakdawalla and a team of researchers found that if private insurers chose to expand their coverage and treat patients at earlier stages of their disease, the move would save Medicare $4 billion to $11 billion in 20 years. Even though the private insurers would save $10 billion to $14 billion in 20 years, their short-run costs would be substantial.

Authors: Gigi A. Moreno, Karen Mulligan, Caroline Huber and Mark T. Linthicum, all of Precision Health Economics; David Dreyfus of Arete Analytics; Timothy, Steven E. Marx, and Yuri Sanchez Gonzalez of AbbVie Inc.; Ron Brookmeyer of University of California at Los Angeles and Lakdawalla.
  • For another study, the researchers examined the costs and benefits of treating hepatitis C patients before they advance into more severe stages of the disease and require a liver transplant. They found that treating hepatitis C patients earlier would avoid liver transplants and thus spare scarce donor livers for use in patients with other liver diseases.

"Systematic HCV screening and treatment could spare 10,490 liver transplants to HCV-infected patients from 2015 to 2035," wrote the research team led by Harvard Medical School associate professor Anupam Jena, who has worked with USC Schaeffer Center on prior studies. "An estimated 7,321 transplants would accrue to patients with end-stage liver disease without HCV."

Authors: Anupam B. Jena of Harvard Medical School; Warren Stevens of Precision Health Economics; Yuri Sanchez Gonzalez, Marx and Juday, all of AbbVie Inc.; Lakdawalla; and Tomas J. Philipson of University of Chicago.
  • In a third study, researchers calculated the value of expanding hepatitis C screening and treatment in the United States. If all individuals were screened and all who were infected were treated at early stages, the social value would reach $824 billion, they estimated.

Authors: Linthicum, Mulligan, and Moreno, all of Precision Health Economics; Dreyfus of Arete Analytics; Sanchez Gonzalez, Juday and Marx, all of AbbVie Inc.; Lakdawalla; Brian R. Edlin of Cornell University and the National Development and Research Institutes; and Brookmeyer.

Lastly, in a commentary, Lakdawalla said that the typical insurance arrangement in which patients share the burden of paying for their treatment will not work. It would "expose patients with HCV to potentially significant financial burdens at a time when they are least able to cope with them," he wrote.

Lakdawalla noted that private insurers currently lack incentives to invest in the latest treatments as patients may change insurers multiple times over the course of their lives.

"Screening the population for hepatitis-C and treating patients early in their disease course poses upfront costs but generates substantial long-term benefits to patients, private insurers, and Medicare," Lakdawalla said. "Policymakers must determine how to encourage private insurers to undertake these short-term costs in the service of substantial long-term benefits. Innovative policies that allow private insurers to harvest the savings they create - even when they accrue to other insurers down the road - may represent a critical strategy for help society unlock the value of cures for hepatitis C and other diseases."
  • Precision Health Economics is a health economics research firm established by Lakdawalla; Dana Goldman, director and distinguished professor of the USC Schaeffer Center; and Tomas Philipson of the University of Chicago. It is currently a part of Precision for Value.

University of Southern California

Related Hepatitis Articles:

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.
Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.
Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
More Hepatitis News and Hepatitis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at